AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38539083 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAF intervention self-guided online (N = 200)
Number of subjects: 500
Study 38539083 — intervention group
Group type: COMPARATOR
Intervention: Emotion reporting control (N = 100)
Number of subjects: 500
Study 38539250 — intervention group
Group type: EXPERIMENTAL
Intervention: AR home-based therapeutic gait-and-balance exergaming intervention
Number of subjects: 24
Study 38539250 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 24
Study 38539415 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study 38539462 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite intervention consisting of non-hormonal pharmacotherapy, digital cognitive behavioral therapy for insomnia (dCBT-I) using Sleepio, self-management strategies via myPatientSpace mobile application, and nomination of an additional support person/partner
Number of subjects: 204
Study 38539462 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite intervention
Number of subjects: 204
Study 38539914 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary antioxidants (high tertiles of DAQI)
Number of subjects: 160
Study 38539914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosmetic treatment (cavitation peeling and sonophoresis with a commercial capillary repair serum)
Number of subjects: 160
Study 38539914 — intervention group
Group type: COMPARATOR
Intervention: Lowest tertile of DAQI
Number of subjects: 160
Study 38540138 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice a day for 4 weeks
Number of subjects: 28
Study 38540138 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 controls)
Number of subjects: 28
Study 38540555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood Lifters (ML) program
Number of subjects: 138
Study 38541769 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-Assisted Hand Rehabilitation
Number of subjects: 0
Study 38541769 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38541803 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise intervention
Number of subjects: 0
Study 38541803 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38541922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified in the abstract
Number of subjects: 0
Study 38541922 — intervention group
Group type: COMPARATOR
Intervention: Control not specified in the abstract
Number of subjects: 0
Study 38542033 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning intervention for predicting length of mechanical ventilation
Number of subjects: 0
Study 38543926 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized Ad5-nCoV (Low-Dose)
Number of subjects: 0
Study 38543926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Ad5-nCoV (Low-Dose)
Number of subjects: 0
Study 38543926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular-Aerosolized Ad5-nCoV (Low-Dose)
Number of subjects: 0
Study 38543926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38544413 — intervention group
Group type: EXPERIMENTAL
Intervention: GORE VIABAHN Endoprosthesis
Number of subjects: 0
Study 38544553 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange with albumin 5% (PE-A5%)
Number of subjects: 10
Study 38544798 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (GLP-1 receptor agonist + supervised exercise)
Number of subjects: 109
Study 38544798 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide alone
Number of subjects: 109
Study 38544798 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Number of subjects: 109
Study 38544798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 38544834 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with chemotherapy plus trastuzumab for breast cancer patients
Number of subjects: 550
Study 38544834 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing (WES) for both breast and prostate cancer patients
Number of subjects: 550
Study 38544919 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) including aspirin and clopidogrel
Number of subjects: 188860
Study 38544919 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 1 (cardiovascular-kidney-metabolic comorbidities)
Number of subjects: 188860
Study 38544919 — intervention group
Group type: EXPERIMENTAL
Intervention: Class 2 (hypertension-dyslipidaemia comorbidities)
Number of subjects: 188860
Study 38544919 — intervention group
Group type: COMPARATOR
Intervention: Class 3 (non-specific comorbidities)
Number of subjects: 188860
Study 38545090 — intervention group
Group type: EXPERIMENTAL
Intervention: BIO101 (350 mg BID)
Number of subjects: 238
Study 38545090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study 38545091 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk-based fortifier (HMBF)
Number of subjects: 228
Study 38545091 — intervention group
Group type: COMPARATOR
Intervention: Bovine milk-based fortifier (BMBF)
Number of subjects: 228
Study 38545092 — intervention group
Group type: EXPERIMENTAL
Intervention: VBI-S (phospholipid nanoparticles) administered intravenously as boluses of 100 ml, 200 ml, 400 ml, and 800 ml until MAP goal was reached.
Number of subjects: 20
Study 38545092 — intervention group
Group type: EXPERIMENTAL
Intervention: VBI-S (phospholipid nanoparticles) administered intravenously.
Number of subjects: 20
Study 38545723 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled hypertension group
Number of subjects: 302
Study 38545723 — intervention group
Group type: COMPARATOR
Intervention: Non-controlled hypertension group
Number of subjects: 302
Study 38545762 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Ecological Momentary Assessments of Pain and Ability to Work
Number of subjects: 0
Study 38545781 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 420 mg subcutaneously monthly or biweekly
Number of subjects: 39
Study 38546220 — intervention group
Group type: EXPERIMENTAL
Intervention: TILT-123 (igrelimogene litadenorepvec) administered intravenously and intratumorally
Number of subjects: 20
Study 38546375 — intervention group
Group type: EXPERIMENTAL
Intervention: Orelabrutinib, dosage and duration not available
Number of subjects: 0
Study 38546421 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Simha Kriya Breathing Practice
Number of subjects: 0
Study 38546428 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Frequency Electrical Acupoint Stimulation
Number of subjects: 0
Study 38546428 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency Electrical Acupoint Stimulation
Number of subjects: 0
Study 38546428 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stimulation)
Number of subjects: 0
Study 38546454 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased nitrate intake from beetroot juice over 4 weeks
Number of subjects: 0
Study 38546454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 38546529 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention not specified; control group not specified.
Number of subjects: 0
Study 38546554 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM)
Number of subjects: 262
Study 38546554 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (HYP)
Number of subjects: 262
Study 38546554 — intervention group
Group type: COMPARATOR
Intervention: Pain psychoeducation (ED)
Number of subjects: 262
Study 38546621 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person group parenting program
Number of subjects: 0
Study 38546621 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth parenting program
Number of subjects: 0
Study 38546621 — intervention group
Group type: COMPARATOR
Intervention: Self-directed online parenting program
Number of subjects: 0
Study 38546622 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 0
Study 38546622 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study 38546803 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole QD (once daily)
Number of subjects: 0
Study 38546803 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 0
Study 38546821 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day fasting-mimicking diet (FMD) programme, monthly cycles as an adjunct to regular care
Number of subjects: 100
Study 38546821 — intervention group
Group type: COMPARATOR
Intervention: Regular care only
Number of subjects: 100
Study 38546822 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cervical tVNS
Number of subjects: 145
Study 38546822 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 145
Study 38546829 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine sublingual film (SL-APO)
Number of subjects: 496
Study 38546897 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical side of the thorax (diaphragmatic excursion measures)
Number of subjects: 40
Study 38546897 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical side of the thorax (phrenic nerve conduction measures)
Number of subjects: 40
Study 38546897 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical side of the thorax (phrenic nerve conduction measures)
Number of subjects: 40
Study 38546897 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative reduction in posterior diaphragmatic excursion
Number of subjects: 40
Study 38546944 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR-Erbitux receptor targeted EnGeneIC Dream Vector with mitoxantrone
Number of subjects: 9
Study 38546960 — intervention group
Group type: EXPERIMENTAL
Intervention: Zanubrutinib (Bruton tyrosine kinase inhibitor)
Number of subjects: 5
Study 38547003 — intervention group
Group type: EXPERIMENTAL
Intervention: liso-cel (CAR T cell therapy)
Number of subjects: 184
Study 38547003 — intervention group
Group type: COMPARATOR
Intervention: standard of care (SOC)
Number of subjects: 184
Study 38547135 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged daily motion modulated stimulation with a multichannel vestibulocochlear implant (VCI) prototype
Number of subjects: 8
Study 38547135 — intervention group
Group type: COMPARATOR
Intervention: Three types of stimulation
Number of subjects: 8
Study 38547208 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of resistance exercise consisting of eight sets of 10 repetitions of unilateral knee extension at 70% of one-repetition maximum.
Number of subjects: 79
Study 38547208 — intervention group
Group type: EXPERIMENTAL
Intervention: Single bout of resistance exercise
Number of subjects: 79
Study 38547208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exercise histidine and sarcosine levels
Number of subjects: 79
Study 38547208 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre/post-exercise fold change in plasma histidine
Number of subjects: 79
Study 38547322 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide (20 mg/ml, 1 ml)
Number of subjects: 249
Study 38547322 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride, 1 ml)
Number of subjects: 249
Study 38547425 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 0
Study 38547453 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-accelerated catheter-directed thrombolysis (UA-CDT)
Number of subjects: 152
Study 38547453 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 152
Study 38547892 — intervention group
Group type: EXPERIMENTAL
Intervention: Gedatolisib plus palbociclib and endocrine therapy (Letrozole for group A, Fulvestrant for groups B-D)
Number of subjects: 103
Study 38547892 — intervention group
Group type: EXPERIMENTAL
Intervention: Gedatolisib plus palbociclib and endocrine therapy
Number of subjects: 103
Study 38547892 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 103
Study 38547892 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related serious adverse events
Number of subjects: 103
Study 38547892 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events
Number of subjects: 103
Study 38547891 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan 6.4 mg/kg (cohort 1)
Number of subjects: 90
Study 38547891 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan 5.4 mg/kg (cohort 1A)
Number of subjects: 90
Study 38547891 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (both cohorts)
Number of subjects: 90
Study 38547893 — intervention group
Group type: EXPERIMENTAL
Intervention: LOAd703 combined with nab-paclitaxel (125 mg/m2) and gemcitabine
Number of subjects: 21
Study 38547893 — intervention group
Group type: EXPERIMENTAL
Intervention: LOAd703
Number of subjects: 21
Study 38547895 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (800 mg intravenously every 2 weeks up to 1 year) plus modified docetaxel, cisplatin, and fluorouracil (mDCF) (eight cycles of 40 mg per m2 docetaxel, 75 mg per m2 cisplatin, and 750 mg per m2 fluorouracil)
Number of subjects: 97
Study 38547895 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab plus mDCF
Number of subjects: 97
Study 38547895 — intervention group
Group type: COMPARATOR
Intervention: mDCF
Number of subjects: 97
Study 38547961 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 0
Study 38547961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38547955 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomography Angiography (CCTA)
Number of subjects: 797
Study 38547955 — intervention group
Group type: COMPARATOR
Intervention: Invasive Coronary Angiography (ICA)
Number of subjects: 797
Study 38548067 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST (FibroScan-aspartate aminotransferase [AST])
Number of subjects: 330
Study 38548067 — intervention group
Group type: EXPERIMENTAL
Intervention: MAST (MRI-AST)
Number of subjects: 330
Study 38548067 — intervention group
Group type: EXPERIMENTAL
Intervention: MEFIB (magnetic resonance elastography [MRE] plus FIB-4)
Number of subjects: 330
Study 38548067 — intervention group
Group type: EXPERIMENTAL
Intervention: FNI (fibrotic NASH index)
Number of subjects: 330
Study 38548135 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching between food items during meals
Number of subjects: 88
Study 38548135 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching between food items during eating in the absence of hunger (EAH)
Number of subjects: 88
Study 38548135 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistency of switching behavior across meals
Number of subjects: 88
Study 38548135 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistency of switching behavior across EAH paradigms
Number of subjects: 88
Study 38548365 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily diary ratings of emotional state and pain severity (children only) at baseline and post
Number of subjects: 280
Study 38548365 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires on quality of life, social support, sleep, and symptoms of anxiety and depression at each time point
Number of subjects: 280
Study 38548365 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised linear regression models for predicting development of CPSP
Number of subjects: 280
Study 38548365 — intervention group
Group type: EXPERIMENTAL
Intervention: K-means classification method for longitudinal data
Number of subjects: 280
Study 38548367 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission non-polypharmacy (<5 medications)
Number of subjects: 85942
Study 38548367 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission polypharmacy (5-10 medications)
Number of subjects: 85942
Study 38548367 — intervention group
Group type: EXPERIMENTAL
Intervention: Preadmission hyperpolypharmacy (>10 medications)
Number of subjects: 85942
Study 38548367 — intervention group
Group type: EXPERIMENTAL
Intervention: New postdischarge polypharmacy
Number of subjects: 85942
Study 38548367 — intervention group
Group type: EXPERIMENTAL
Intervention: New postdischarge hyperpolypharmacy
Number of subjects: 85942
Study 38548367 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher level of medication use
Number of subjects: 85942
Study 38548404 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose azacitidine 50 mg/m plus venetoclax
Number of subjects: 35
Study 38548404 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose azacitidine plus venetoclax
Number of subjects: 35
Study 38548406 — intervention group
Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 80
Study 38548406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 38548524 — intervention group
Group type: EXPERIMENTAL
Intervention: patisiran 0.3 mg/kg intravenously every 3 weeks for 18 months
Number of subjects: 18
Study 38548524 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 38548948 — intervention group
Group type: EXPERIMENTAL
Intervention: Velvet-soft PVC tube (group V)
Number of subjects: 149
Study 38548948 — intervention group
Group type: COMPARATOR
Intervention: PVC tube (group P)
Number of subjects: 149
Study 38548948 — intervention group
Group type: COMPARATOR
Intervention: PVC tube attached to a rubber catheter (group PR)
Number of subjects: 149
Study 38549070 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage contact lenses (BCLs)
Number of subjects: 69
Study 38549070 — intervention group
Group type: COMPARATOR
Intervention: Gauze (control group)
Number of subjects: 69
Study 38549121 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 0
Study 38549122 — intervention group
Group type: EXPERIMENTAL
Intervention: LOCI plus MBC training and technical assistance
Number of subjects: 21
Study 38549122 — intervention group
Group type: COMPARATOR
Intervention: MBC training and technical assistance only
Number of subjects: 21
Study 38549122 — intervention group
Group type: EXPERIMENTAL
Intervention: LOCI
Number of subjects: 21
Study 38549128 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation (PNS)
Number of subjects: 90
Study 38549128 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 90
Study 38549745 — intervention group
Group type: EXPERIMENTAL
Intervention: E304i food additive
Number of subjects: 0
Study 38549835 — intervention group
Group type: EXPERIMENTAL
Intervention: FBN (Feature-Based Network) models with 32, 64, 128, and 256 gray levels
Number of subjects: 0
Study 38549835 — intervention group
Group type: COMPARATOR
Intervention: FBS (Feature-Based Segmentation) models
Number of subjects: 0
Study 38549835 — intervention group
Group type: EXPERIMENTAL
Intervention: Parameter-optimized model (FBN = 64 and FBN = 128)
Number of subjects: 0
Study 38549835 — intervention group
Group type: EXPERIMENTAL
Intervention: Kaplan-Meier analyses
Number of subjects: 0
Study 38550293 — intervention group
Group type: EXPERIMENTAL
Intervention: ECD-focused parenting and nutrition education delivered by local Community Health Workers (CHWs) for one year, with fortnightly home visits.
Number of subjects: 599
Study 38550293 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 599
Study 38550328 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccine intervention delivery
Number of subjects: 0
Study 38550605 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week arm (34Gy in 10 fractions over 2 weeks)
Number of subjects: 1121
Study 38550605 — intervention group
Group type: COMPARATOR
Intervention: 3-week arm (35Gy in 15 fractions over 3 weeks)
Number of subjects: 1121
Study 38550709 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpectoral and pectoserratus plane block (IPP/PSP)
Number of subjects: 57
Study 38550709 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic infiltration
Number of subjects: 57
Study 38550899 — intervention group
Group type: EXPERIMENTAL
Intervention: LIVE intervention (multicomponent intervention implemented by municipal coordinators over a 6-month period)
Number of subjects: 280
Study 38551015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 1720
Study 38551015 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1720
Study 38551365 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine self-administration behavior; specific dosage and duration not available.
Number of subjects: 0
Study 38551394 — intervention group
Group type: EXPERIMENTAL
Intervention: TPST-1120 monotherapy
Number of subjects: 39
Study 38551394 — intervention group
Group type: EXPERIMENTAL
Intervention: TPST-1120 in combination with nivolumab
Number of subjects: 39
Study 38551394 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study 38551501 — intervention group
Group type: EXPERIMENTAL
Intervention: CAR-GD2 T-cell therapy
Number of subjects: 0
Study 38551501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tazemetostat (EZH2 inhibitor)
Number of subjects: 0
Study 38551501 — intervention group
Group type: EXPERIMENTAL
Intervention: AP1903 (dimerizing drug)
Number of subjects: 0
Study 38551522 — intervention group
Group type: EXPERIMENTAL
Intervention: HF cardiologists and family doctors' estimates of patient 1-year mortality
Number of subjects: 1643
Study 38551522 — intervention group
Group type: EXPERIMENTAL
Intervention: Female HF cardiologists making predictions on male patients
Number of subjects: 1643
Study 38551522 — intervention group
Group type: EXPERIMENTAL
Intervention: HF cardiologist estimates in Black patients
Number of subjects: 1643
Study 38551522 — intervention group
Group type: EXPERIMENTAL
Intervention: High-confidence estimates
Number of subjects: 1643
Study 38551563 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesion PCI before complete CAG
Number of subjects: 184
Study 38551563 — intervention group
Group type: COMPARATOR
Intervention: Complete CAG followed by culprit lesion PCI
Number of subjects: 184
Study 38551588 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 informational emails encouraging households to switch to CSR plans
Number of subjects: 42470
Study 38551588 — intervention group
Group type: COMPARATOR
Intervention: No-email control group
Number of subjects: 42470